Acute toxicity of $ C_{60} $–Cis-Pt nanocomplex in vivo
Abstract Acute toxicity of noncovalent nanocomplex of $ C_{60} $ fullerene with Cisplatin (Cis-Pt) (the ratio of compounds $ C_{60} $:Cis-Pt by weight 1:1) in a dose progression (7.5 + 7.5, 15.0 + 15.0, 22.5 + 22.5, 30.0 + 30.0, 37.5 + 37.5, and 45.0 + 45.0 mg/kg) was investigated in mice of BALB/c line. Mice were injected with $ C_{60} $–Cis-Pt nanocomplex or free Cis-Pt at the same doses single intraperitoneally and observed for 14 days. A comparative study of the toxicity of free Cis-Pt and Cis-Pt at noncovalent complexation with $ C_{60} $ fullerene ($ C_{60} $–Cis-Pt nanocomplex) demonstrated halving the toxicity of $ C_{60} $–Cis-Pt nanocomplex in comparison with free Cis-Pt: $ LD_{50} $ (Cis-Pt) 15.6 ± 1.3 mg/kg vs $ LD_{50} $ ($ C_{60} $–Cis-Pt) 36.1 ± 2.8 mg/kg. The toxic effects of $ C_{60} $–Cis-Pt nanocomplex and free Cis-Pt were detected at doses 22.5 + 22.5 mg/kg and 15.0 mg/kg, respectively, and were accompanied by impaired mice behavior, decreased body weight and animal survival, hematotoxicity, and pathological changes in heart, liver, spleen, and kidneys. It was shown that $ C_{60} $ fullerene complexed with Cis-Pt prevented drug-induced decrease in animal survival, anemia, thrombocytosis, and leukopenia development, as well as inflammatory processes in spleen, heart, kidney, and liver. The obtained results indicate the prospects for using noncovalent nanocomplex $ C_{60} $–Cis-Pt in antitumor therapy at low therapeutic doses of Cis-Pt..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Applied nanoscience - 12(2021), 3 vom: 02. Feb., Seite 439-447 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lynchak, Oksana [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: |
50.94 / Mikrosystemtechnik / Nanotechnologie / Mikrosystemtechnik / Nanotechnologie |
---|---|
Themen: |
C |
Anmerkungen: |
© King Abdulaziz City for Science and Technology 2021 |
---|
doi: |
10.1007/s13204-021-01680-3 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2129695752 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2129695752 | ||
003 | DE-627 | ||
005 | 20240403084334.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230505s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s13204-021-01680-3 |2 doi | |
035 | |a (DE-627)OLC2129695752 | ||
035 | |a (DE-He213)s13204-021-01680-3-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 540 |q VZ |
084 | |a 50.94 |2 bkl | ||
100 | 1 | |a Lynchak, Oksana |e verfasserin |0 (orcid)0000-0002-1495-3190 |4 aut | |
245 | 1 | 0 | |a Acute toxicity of $ C_{60} $–Cis-Pt nanocomplex in vivo |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © King Abdulaziz City for Science and Technology 2021 | ||
520 | |a Abstract Acute toxicity of noncovalent nanocomplex of $ C_{60} $ fullerene with Cisplatin (Cis-Pt) (the ratio of compounds $ C_{60} $:Cis-Pt by weight 1:1) in a dose progression (7.5 + 7.5, 15.0 + 15.0, 22.5 + 22.5, 30.0 + 30.0, 37.5 + 37.5, and 45.0 + 45.0 mg/kg) was investigated in mice of BALB/c line. Mice were injected with $ C_{60} $–Cis-Pt nanocomplex or free Cis-Pt at the same doses single intraperitoneally and observed for 14 days. A comparative study of the toxicity of free Cis-Pt and Cis-Pt at noncovalent complexation with $ C_{60} $ fullerene ($ C_{60} $–Cis-Pt nanocomplex) demonstrated halving the toxicity of $ C_{60} $–Cis-Pt nanocomplex in comparison with free Cis-Pt: $ LD_{50} $ (Cis-Pt) 15.6 ± 1.3 mg/kg vs $ LD_{50} $ ($ C_{60} $–Cis-Pt) 36.1 ± 2.8 mg/kg. The toxic effects of $ C_{60} $–Cis-Pt nanocomplex and free Cis-Pt were detected at doses 22.5 + 22.5 mg/kg and 15.0 mg/kg, respectively, and were accompanied by impaired mice behavior, decreased body weight and animal survival, hematotoxicity, and pathological changes in heart, liver, spleen, and kidneys. It was shown that $ C_{60} $ fullerene complexed with Cis-Pt prevented drug-induced decrease in animal survival, anemia, thrombocytosis, and leukopenia development, as well as inflammatory processes in spleen, heart, kidney, and liver. The obtained results indicate the prospects for using noncovalent nanocomplex $ C_{60} $–Cis-Pt in antitumor therapy at low therapeutic doses of Cis-Pt. | ||
650 | 4 | |a C | |
650 | 4 | |a fullerene | |
650 | 4 | |a Cisplatin | |
650 | 4 | |a Nanocomplex | |
650 | 4 | |a LD | |
650 | 4 | |a value | |
650 | 4 | |a Hematological and histological analysis | |
700 | 1 | |a Byelinska, Iryna |0 (orcid)0000-0003-3551-1161 |4 aut | |
700 | 1 | |a Dziubenko, Natalya |0 (orcid)0000-0002-2998-4168 |4 aut | |
700 | 1 | |a Kuznietsova, Halyna |0 (orcid)0000-0002-1296-1007 |4 aut | |
700 | 1 | |a Abramchuk, Olga |0 (orcid)0000-0002-9479-2111 |4 aut | |
700 | 1 | |a Prylutska, Svitlana |0 (orcid)0000-0001-5280-8341 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Applied nanoscience |d Springer International Publishing, 2011 |g 12(2021), 3 vom: 02. Feb., Seite 439-447 |h Online-Ressource |w (DE-627)658009001 |w (DE-600)2607723-1 |w (DE-576)343627167 |x 2190-5517 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2021 |g number:3 |g day:02 |g month:02 |g pages:439-447 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13204-021-01680-3 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_152 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_266 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2107 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2433 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2472 | ||
912 | |a GBV_ILN_2474 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4328 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
936 | b | k | |a 50.94 |j Mikrosystemtechnik |j Nanotechnologie |j Mikrosystemtechnik |j Nanotechnologie |q VZ |
951 | |a AR | ||
952 | |d 12 |j 2021 |e 3 |b 02 |c 02 |h 439-447 |